PharmaCyte Stock Soars 30% as Cash Dips and FDA Hold Persists
By ATTN Desk · Editorial oversight: Sean Han
Introduction
PharmaCyte Biotech Inc. (NASDAQ: PMCB) is a clinical-stage biotechnology company headquartered in Las Vegas, Nevada. As of December 4, 2025, its share price stood at $1.0199, reflecting a 29.99% increase on a volume of 3,258,851 shares. PharmaCyte develops cellular therapies for cancer and diabetes using its proprietary Cell-in-a-Box® live cell encapsulation platform.
| Ticker | Exchange | Price (Dec 4, 2025) | Change (%) | Volume | 52-Week Range |
|---|---|---|---|---|---|
| PMCB | NAS | $1.0199 | +29.99% | 3,258,851 | $0.63–$1.90 |
Corporate Structure
Founded in 1996, PharmaCyte operates with a team of 2–10 employees. The company’s executive offices and laboratories are located at 3960 Howard Hughes Parkway, Suite 500, Las Vegas, NV 89169. Key beneficial owners disclosed in a Schedule 13G/A filing dated November 7, 2025, include Mitchell P. Kopin and Daniel B. Asher—each holding 9.99% of outstanding shares—as well as Intracoastal Capital LLC with a similar stake. On November 18, 2025, PharmaCyte amended a Schedule 13D/A to report a 74% ownership interest in Q/C Technologies, Inc., acquired for $3 million.
Biotechnology by Louis Reed
Recent Developments and News
On March 17, 2025, PharmaCyte filed its Form 10-Q for the quarter ended January 31, 2025, reporting no revenues and operating expenses of $960,252, a decrease from the prior year’s quarter. Net other expenses totaled $2,085,076 for that period, compared to income of $1,249,409 in the prior-year quarter. Cash and cash equivalents declined from $50.2 million on April 30, 2024, to $16.4 million on January 31, 2025, attributed to preferred stock redemptions, share repurchases (129,365 shares), investment activities, and research and development costs.
An FDA clinical hold remains in place on the company’s Investigational New Drug application for locally advanced, inoperable pancreatic cancer. PharmaCyte has submitted additional studies and data to address the hold. On November 18, 2025, the company also disclosed an amendment to Form 8-K reflecting material weaknesses in internal controls and ongoing efforts to remediate them.
Financial and Strategic Analysis
With an intraday market capitalization near $6 million and a trailing P/E ratio of 14.83, PharmaCyte is classified as a micro-cap issuer with limited current revenues. Key metrics (TTM) include:
- Earnings per share: $0.06
- Profit margin: 0.00%
- Return on assets: –4.29%
- Return on equity: –2.33%
- Total cash (MRQ): $13.44 million
- Levered free cash flow (TTM): –$13.99 million
- Price/book (MRQ): 0.14
The company focuses on its Cell-in-a-Box® technology, which encapsulates genetically engineered human cells to activate prodrugs at tumor sites or to regulate insulin release in diabetic patients. The stake in Q/C Technologies reflects a broader acquisition strategy aimed at strengthening its biotech portfolio. Ongoing investment agreements, including a Securities Purchase Agreement with TNF Pharmaceuticals, signal efforts to advance clinical programs.
Market Position and Industry Context
PharmaCyte operates in the biotechnology research sector, competing with other developers of cancer and diabetes therapies. Its Cell-in-a-Box® platform offers a targeted chemotherapy approach for pancreatic and other cancers, as well as a potential bio-artificial pancreas for Type 1 and insulin-dependent Type 2 diabetes. The company’s low beta (0.05) indicates limited share price correlation with broader market fluctuations; however, its micro-cap status and reliance on clinical outcomes introduce potential volatility and funding challenges. The outcomes of its FDA application and management of identified internal-control deficiencies will be integral to the company’s commercialization prospects.
tl;dr
On December 4, 2025, PMCB shares rose 29.99% to $1.0199 on significant volume. The January 31, 2025 10-Q showed no revenue, operating expenses of $960,252, and $16.4 million in cash. An FDA clinical hold on the pancreatic cancer trial is under review with supplemental data. Major shareholders increased positions in November 2025, including a 74% stake in Q/C Technologies. The company’s cash runway will depend on upcoming clinical milestones and additional financing.